Full Breakdown
Moderna's mRNA Flu Vaccine Gains Unanimous FDA Advisory Support
6/19/2026, 4:43:44 AM
FDA Advisory Panel Recommends Moderna's mRNA Flu Vaccine
On June 18, 2026 the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 9-0 to recommend Moderna’s mRNA-1010 (mFlusiva) for adults 50-64 and accelerated approval for adults 65 and older, concluding that benefits outweigh risks.
Background & Context
Moderna’s application was initially rejected for using a standard-dose comparator instead of the high-dose vaccine recommended for seniors. The decision, made under HHS Secretary Robert F. Kennedy Jr. and FDA vaccine chief Vinay Prasad, was reversed after pressure. Acting leaders—Kyle Diamantas, Karim Mikhail, and Marty Makary’s successor—have shifted the agency’s stance.
Clinical Evidence
Trials in 40,274 adults >= 50 and 2,987 adults >= 65 showed a 27 % reduction in influenza versus standard-dose shots and a stronger immune response than high-dose vaccines. Safety was mild, transient reactions with no serious events. Limited data exist for immunocompromised people and influenza B.
Official Statements & Responses
Moderna thanked panel for its “thoughtful review” and affirmed confidence in data. FDA staff praised efficacy robustness but noted gaps for frail seniors and influenza B. Secretary Kennedy has called mRNA COVID-19 vaccines “the deadliest” and cut $500 million in mRNA research. CDC officials highlighted high flu-hospitalization burden among older adults.
Criticism & Opposition
Critics argue standard-dose comparator undervalues the high-dose vaccine for seniors and that trial termination limits assessment of long-term protection. They also note limited data for immunocompromised patients and no influenza B efficacy.
Conflicting Reports & Gaps
Sources differ on why the FDA initially rejected the application—some cite the comparator issue, others cite scrutiny under Kennedy. Reviewers flagged insufficient data for frail older adults, immunocompromised patients, and influenza B, while advisory panel deemed the evidence sufficient.
Verbatim Quotes
- “The studies that were presented today were very well conducted. They have very clear results that are very robust,” — Flor Munoz-Rivas, pediatric infectious-disease physician, Baylor College of Medicine
- “Putting it all together, the benefits outweigh the problems, the risks, in my opinion” — Stanley Perlman, pediatric disease expert, University of Iowa
- “We appreciate the thoughtful review by the members of VRBPAC and their recognition of the clinical evidence supporting mRNA-1010,” — Stéphane Bancel, CEO, Moderna
- “FDA does not always follow VRBPAC, but they should be looking at the data, not sentiment, in assessing the vaccine,” — Dorit Reiss, vaccine-policy expert, University of California, San Francisco
Why It Matters
The mRNA platform shortens manufacturing to 2-3 months after strain selection, enabling mid-season updates and matching of circulating viruses. Faster production also improves preparedness for pandemic influenza strains.
What’s Next
The FDA must decide by August 5, 2026. A CDC advisory committee recommendation will follow before national use. Moderna will start a confirmatory trial in seniors this year, with results expected over the 2026-2027 flu seasons.
